title: [Evaluation of chemoembolization as an adjuvant therapy for primary liver carcinoma after surgical resection].
abstract: In order to decrease the intrahepatic recurrence rate after surgical resection of hepatoma, from October 1989 to December 1992, 219 patients were recruited to a prospective trial to evaluate transcatheter hepatic arterial chemo-embolization (TCE) as a postoperative adjuvant therapy for primary liver carcinoma. These patients who underwent radical or palliative resection were divided into 3 groups: (1) Resection of tumor; (2) TCE three to four weeks after resection; (3) Relapse after resection plus TCE. This study presented the principle, techniques and results of TCE. The intrahepatic recurrence rate was 58.6% in group I and 9.5% in group II (P < 0.001). The 1-, 2-, 3-year-survival rates were 67.2%, 52.0%, 42.8% of the patients in group I, while 95.2%, 84.7%, 67.7% in the patients in group II (P < 0.05). The 1-, 2-, 3-year-survival rates were 21.5%, 0%, 0% of the patients who underwent palliative. resection only, while 66.7%, 41.7% of the patients in group III (P < 0.001). Taken together, adjuvaut chemoembolization helps decrease the recurrence rate and increase the survival rate in patients with primary liver cancer treated with surgical resection.
authors.affiliation: Tumor Hospital, Sun Yat-sen University of Medical Sciences, Guangzhou.
authors.forename: J Q
authors.initials: JQ
authors.lastname: Li
authors.forename: Y Q
authors.initials: YQ
authors.lastname: Zhang
authors.forename: W Z
authors.initials: WZ
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D017024:Chemotherapy, Adjuvant; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D016685:Mitomycin; D004317:Doxorubicin